Transcranial direct-current stimulation | |
---|---|
MeSH | D065908 |
Transcranial direct current stimulation (tDCS) is a form of neuromodulation that uses constant, low direct current delivered via electrodes on the head. It was originally developed to help patients with brain injuries or neuropsychiatric conditions such as major depressive disorder. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way, as well as transcranial magnetic stimulation. [1]
Research shows increasing evidence for tDCS as a treatment for depression. [2] [3] [4] There is mixed evidence about whether tDCS is useful for cognitive enhancement in healthy people. There is no strong evidence that tDCS is useful for memory deficits in Parkinson's disease and Alzheimer's disease, [5] non-neuropathic pain, [6] nor for improving arm or leg functioning and muscle strength in people recovering from a stroke. [7] There is emerging supportive evidence for tDCS in the management of schizophrenia –especially for negative symptoms. [8] [9]
There is some evidence tDCS might be of moderate benefit as treatment for mild and moderate Depression, [10] major depressive disorder [11] and treatment-resistant depression. [12]
Recent research on tDCS has shown promising results in treating other mental health conditions such as anxiety [10] and PTSD. [13] More research is required on the topic. There is also evidence that tDCS is useful in treating neuropathic pain after spinal cord injury. [14] There is evidence of very low to moderate quality that tDCS can improve activities of daily living assessment in the short-term after stroke. [15] [7]
Transcranial direct-current stimulaiton is also used to augment speech therapy in patients with acquired language disorders like aphasia, or to help maintain language abilities in the case of primary progressive aphasia, a neurodegenerative condition. [16]
According to the British National Institute for Health and Care Excellence (NICE), the evidence on tDCS for depression raises no major safety concerns. [17]
As of 2017, at stimulation up to 60 min and up to 4 mA over two weeks, adverse effects include skin irritation, a phosphene at the start of stimulation, nausea, headache, dizziness, and itching under the electrode. Typical treatment sessions lasting for about 20–30 minutes repeated daily for several weeks in the treatment of depression. [18] Adverse effects of long term treatment were not known as of 2017. [19] Nausea most commonly occurs when the electrodes are placed above the mastoid for stimulation of the vestibular system. A phosphene is a brief flash of light that can occur if an electrode is placed near the eye. [20] [21]
People susceptible to seizures, such as people with epilepsy should not receive tDCS. [20] Studies have been completed to determine the current density at which overt brain damage occurs in rats. It was found that in cathodal stimulation, a current density of 142.9 A/m2 delivering a charge density of 52400 C/m2 or higher caused a brain lesion in the rat. This is over two orders of magnitude higher than protocols that were in use as of 2009. [22] [23] [24]
tDCS stimulates and activates brain cells by delivering electrical signals. The lasting modulation of cortical excitability produced by tDCS makes it an effective solution to facilitate rehabilitation and treat a range of neuropsychiatric disorders. [25] The way that the stimulation changes brain function is either by causing the neuron’s resting membrane potential to depolarize or hyperpolarize. When positive stimulation (anodal tDCS) is delivered, the current causes a depolarization of the resting membrane potential, which increases neuronal excitability and allows for more spontaneous cell firing. When negative stimulation (cathodal tDCS) is delivered, the current causes a hyperpolarization of the resting membrane potential. This decreases neuron excitability due to the decreased spontaneous cell firing. [20] [26]
In case of treating depression, tDCS currents specifically target the left side of dorsolateral prefrontal cortex (DLPFC) located in the frontal lobe. Left DLPFC has been shown to be associated with lower activity in the depressed population. [27] [11]
tDCS is able to achieve cortical changes even after the stimulation is ended. The duration of this change depends on the length of stimulation as well as the intensity of stimulation. The effects of stimulation increase as the duration of stimulation increases or the strength of the current increases. [28] tDCS has been proposed to promote both long term potentiation and long term depression, [20] [26] and further research is needed for validation.
Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain. [20]
Transcranial direct current stimulation is a relatively simple technique requiring only a few parts. These include two electrodes and a battery-powered device that delivers constant current. Control software can also be used in experiments that require multiple sessions with differing stimulation types so that neither the person receiving the stimulation nor the experimenter knows which type is being administered. Each device has an anodal, positively charged electrode and a cathodal, negative electrode. Current is "conventionally" described as flowing from the positive anode, through the intervening conducting tissue, to the cathode, creating a circuit. Note that in traditional electric circuits constructed from metal wires, charge drift is created by the motion of negatively charged electrons, which actually flow from cathode to anode. However, in biological systems, such as the head, current is usually created by the flow of ions, which may be positively or negatively charged –positive ions will flow towards the cathode; negative ions will flow toward the anode. The device may control the current as well as the duration of stimulation. [29]
To set up the tDCS device, the electrodes and the skin need to be prepared. This ensures a low resistance connection between the skin and the electrode. The careful placement of the electrodes is crucial to successful tDCS technique. The electrode pads come in various sizes with benefits to each size. A smaller sized electrode achieves a more focused stimulation of a site while a larger electrode ensures that the entirety of the region of interest is being stimulated. [30] If the electrode is placed incorrectly, a different site or more sites than intended may be stimulated resulting in faulty results. [20] One of the electrodes is placed over the region of interest and the other electrode, the reference electrode, is placed in another location in order to complete the circuit. This reference electrode is usually placed on the neck or shoulder of the opposite side of the body than the region of interest. Since the region of interest may be small, it is often useful to locate this region before placing the electrode by using a brain imaging technique such as fMRI or PET. [20] Once the electrodes are placed correctly, the stimulation can be started. Many devices have a built-in capability that allows the current to be "ramped up" or increased gradually until the necessary current is reached. This decreases the amount of stimulation effects felt by the person receiving the tDCS. [31] After the stimulation has been started, the current will continue for the amount of time set on the device and then will automatically be shut off. Recently a new approach has been introduced where instead of using two large pads, multiple (more than two) smaller sized gel electrodes are used to target specific cortical structures. This new approach is called High Definition tDCS (HD-tDCS). [30] [32] In a pilot study, HD-tDCS was found to have greater and longer lasting motor cortex excitability changes than sponge tDCS. [33]
There are three different types of stimulation: anodal, cathodal, and sham. The anodal stimulation is positive (V+) stimulation that increases the neuronal excitability of the area being stimulated. Cathodal (V−) stimulation decreases the neuronal excitability of the area being stimulated. Cathodal stimulation can treat psychiatric disorders that are caused by the hyper-activity of an area of the brain. [34] Sham stimulation is used as a control in experiments. Sham stimulation emits a brief current but then remains off for the remainder of the stimulation time. With sham stimulation, the person receiving the tDCS does not know that they are not receiving prolonged stimulation. By comparing the results in subjects exposed to sham stimulation with the results of subjects exposed to anodal or cathodal stimulation, researchers can see how much of an effect is caused by the current stimulation, rather than by the placebo effect.
Recently, tDCS devices are being researched and created intended for at-home use –ranging from treating medical conditions such as depression to enhancing general cognitive well-being. [35] [36] Clinical trials are needed to establish the efficacy, feasibility and acceptability of home-based tDCS treatment. [37]
The basic design of tDCS, using direct current (DC) to stimulate the area of interest, has existed for over 100 years. There were a number of rudimentary experiments completed before the 19th century using this technique that tested animal and human electricity. Luigi Galvani and Alessandro Volta were two such researchers that utilized the technology of tDCS in their explorations of the source of animal cell electricity [citation needed]. It was due to these initial studies that tDCS was first brought into the clinical scene. In 1801, Giovanni Aldini (Galvani's nephew) started a study in which he successfully used the technique of direct current stimulation to improve the mood of melancholy patients. [38]
There was a brief rise of interest in transcranial direct current stimulation in the 1960s when studies by researcher D. J. Albert proved that the stimulation could affect brain function by changing the cortical excitability. [39] He also discovered that positive and negative stimulation had different effects on the cortical excitability. [40]
Research continued, further fueled by knowledge gained from other techniques like TMS and fMRI. [28] [20]
In transcranial magnetic stimulation (TMS), an electric coil is held above the region of interest on the scalp that uses rapidly changing magnetic fields to induce small electrical currents in the brain. There are two types of TMS: repetitive TMS and single pulse TMS. Both are used in research therapy but effects lasting longer than the stimulation period are only observed in repetitive TMS. Similar to tDCS, an increase or decrease in neuronal activity can be achieved using this technique, but the method of how this is induced is very different. Transcranial direct current stimulation has the two different directions of current that cause the different effects. Increased neuronal activity is induced in repetitive TMS by using a higher frequency and decreased neuronal activity is induced by using a lower frequency. [29]
Variants related to tDCS include tACS, tPCS and transcranial random noise stimulation (tRNS), a group of technologies commonly referred to as transcranial electrical stimulation, or TES. [41]
Determining the safety and effectiveness of tDCS treatment for people with depression is being investigated:
There is mixed evidence about whether tDCS is useful for cognitive enhancement in healthy people. Several reviews have found evidence of small yet significant cognitive improvements. [45] [46] [47] [48] Other reviews found no evidence at all, [49] [50] although one of them [50] has been criticized for overlooking within-subject effects [51] and evidence from multiple-session tDCS trials. However, the original authors addressed these raised concerns in a further analysis and continued to find no evidence of impact [52]
A 2015 review of results from hundreds of tDCS experiments found that there was no statistically conclusive evidence to support any net cognitive effect, positive or negative, of single session tDCS in healthy populations –there is no evidence that tDCS is useful for cognitive enhancement. [50] A second study by the same authors found there was little-to-no statistically reliable impact of tDCS on any neurophysiologic outcome. [49]
There is no strong evidence that tDCS is useful for memory deficits in Alzheimer's disease, [5] schizophrenia, [53] non-neuropathic pain. [6] A few clinical trials have been conducted on the use of tDCS to ameliorate memory deficits in Parkinson's disease and Alzheimer's disease and healthy subjects, with mixed results. [5] Research conducted as of 2013 in schizophrenia, has found that while large effect sizes were initially found for symptom improvement, later and larger studies have found smaller effect sizes (see also section on use of tDCS in psychiatric disorders below). [53] Studies have mostly concentrated on positive symptoms like auditory hallucinations; research on negative symptoms is lacking. [53]
There is no strong evidence that tDCS can help improve upper limb function after stroke. [54] [55] In stroke, research conducted as of 2014, has found that tDCS is not effective for improving upper limb function after stroke. [54] [55] While some reviews have suggested an effect of tDCS for improving post-stroke aphasia, a 2015 Cochrane review could find no improvement from combining tDCS with conventional treatment. [56] [55] [57] Research conducted as of 2013 suggests that tDCS may be effective for improve vision deficits following stroke. [55]
Motor Learning and Memory Function
There is evidence that certain tDCS montages can increase learning rates for particular tasks in healthy individuals, namely motor tasks and memory function. [58] However, reproducibility remains to be fully tested across studies and standardization for these kinds of studies has not been implemented fully, though an attempt at formalizing standards was released in 2017. [58]
Research conducted as of 2012 on the use of tDCS to treat pain, found that the research has been of low quality and cannot be used as a basis to recommend use of tDCS to treat pain. [6] In chronic pain following spinal cord injury, research is of high quality and has found tDCS to be ineffective. [59] tDCS has also been studied in addiction. [60] [61] There is some moderate (level B) evidence to indicate that, in addition to treating major depressive disorder, tDCS may also be appropriate to treat fibromyalgia, and craving disorders. [62]
tDCS has been used in neuroscience research, particularly to try to link specific brain regions to specific cognitive tasks [63] or psychological phenomena. [64] The cerebellum has been a focus of research, due to its high concentration of neurons, its location immediately below the skull, and its multiple reciprocal anatomical connections to motor and associative parts of the brain. [65] Most such studies focus on the impact of cerebellar tDCS on motor, cognitive, and affective functions in healthy and patient populations, but some also employ tDCS over the cerebellum to study the functional connectivity of the cerebellum to other areas of the brain. [66]
While growing literature shows the efficacy of transcranial direct current stimulation (tDCS) for treating nervous diseases such as acute depressive episodes, the lack of knowledge about the nature of this treatment at the cell level [1] raises concerns regarding possible adverse effects that would appear long after the treatment has ended.
First, tDCS therapy involves exposure of the brain to an intense electric field, which is several times and even orders of magnitude higher than natural ones in the brain. [67] [68] While the therapeutic effect is observed in a short period of months, the impact of the electric fields on the brain, specifically on the treated neuronal structures, is a question of further long-term research.
Second, tDCS brain tissue stimulation targets a large area of poorly characterized tissue. [67] [69] Therefore, it is unclear whether electrical fields reach only the neural structures of the brain that need treatment. The radiation can destroy healthy cells which don't need treatment during tDCS therapy. [69]
tDCS is a CE approved treatment for major depressive disorder (MDD) in the UK, EU, Australia, and Mexico. As of 2015, tDCS has not been approved for any use by the US FDA. [57] An FDA briefing document prepared in 2012 stated that "there is no regulation for therapeutic tDCS". [70]
Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Introduced by a group of US clinicians in the mid-1970s, the term was adopted by the American Psychiatric Association for this symptom cluster under mood disorders in the 1980 version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), and has become widely used since. The disorder causes the second-most years lived with disability, after lower back pain.
Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to induce an electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil connected to the scalp. The stimulator generates a changing electric current within the coil which creates a varying magnetic field, inducing a current within a region in the brain itself.
Deep brain stimulation (DBS) is a surgical procedure that implants a neurostimulator and electrodes which sends electrical impulses to specified targets in the brain responsible for movement control. The treatment is designed for a range of movement disorders such as Parkinson's disease, essential tremor, and dystonia, as well as for certain neuropsychiatric conditions like obsessive-compulsive disorder (OCD) and epilepsy. The exact mechanisms of DBS are complex and not entirely clear, but it is known to modify brain activity in a structured way.
Cranial electrotherapy stimulation (CES) is a form of neurostimulation that delivers a small, pulsed, alternating current via electrodes on the head. CES is used with the intention of treating a variety of conditions such as anxiety, depression and insomnia. CES has been suggested as a possible treatment for headaches, fibromyalgia, smoking cessation, and opiate withdrawal, but there is little evidence of effectiveness for many of these conditions and the evidence for use in acute depression is not sufficient to justify it.
Brodmann area 46, or BA46, is part of the frontal cortex in the human brain. It is between BA10 and BA45.
Neurotechnology encompasses any method or electronic device which interfaces with the nervous system to monitor or modulate neural activity.
Neurohacking is a subclass of biohacking, focused specifically on the brain. Neurohackers seek to better themselves or others by “hacking the brain” to improve reflexes, learn faster, or treat psychological disorders. The modern neurohacking movement has been around since the 1980s. However, herbal supplements have been used to increase brain function for hundreds of years. After a brief period marked by a lack of research in the area, neurohacking started regaining interest in the early 2000s. Currently, most neurohacking is performed via do-it-yourself (DIY) methods by in-home users.
Psychotic depression, also known as depressive psychosis, is a major depressive episode that is accompanied by psychotic symptoms. It can occur in the context of bipolar disorder or major depressive disorder. It can be difficult to distinguish from schizoaffective disorder, a diagnosis that requires the presence of psychotic symptoms for at least two weeks without any mood symptoms present. Unipolar psychotic depression requires that psychotic symptoms occur during severe depressive episodes, although residual psychotic symptoms may also be present in between episodes. Diagnosis using the DSM-5 involves meeting the criteria for a major depressive episode, along with the criteria for "mood-congruent or mood-incongruent psychotic features" specifier.
Brodmann area 25 (BA25) is the subgenual area, area subgenualis or subgenual cingulate area in the cerebral cortex of the brain and delineated based on its cytoarchitectonic characteristics.
Treatment-resistant depression (TRD) is major depressive disorder in which an affected person does not respond adequately to at least two different antidepressant medications at an adequate dose and for an adequate duration. Inadequate response has most commonly been defined as less than 25% reduction in depressive symptoms following treatment with an antidepressant. Many clinicians and researchers question the construct validity and clinical utility of treatment-resistant depression as currently conceptualized.
Management of depression is the treatment of depression that may involve a number of different therapies: medications, behavior therapy, psychotherapy, and medical devices.
Late-life depression refers to depression occurring in older adults and has diverse presentations, including as a recurrence of early-onset depression, a new diagnosis of late-onset depression, and a mood disorder resulting from a separate medical condition, substance use, or medication regimen. Research regarding late-life depression often focuses on late-onset depression, which is defined as a major depressive episode occurring for the first time in an older person.
Neurostimulation is the purposeful modulation of the nervous system's activity using invasive or non-invasive means. Neurostimulation usually refers to the electromagnetic approaches to neuromodulation.
Restorative neurology is a branch of neurology dedicated to improving functions of the impaired nervous system through selective structural or functional modification of abnormal neurocontrol according to underlying mechanisms and clinically unrecognized residual functions. When impaired, the body naturally reconstructs new neurological pathways and redirects activity. The field of restorative neurology works to accentuate these new pathways and primarily focuses on the theory of the plasticity of an impaired nervous system. Its main goal is to take a broken down and disordered nervous system and return it to a state of normal function. Certain treatment strategies are used to augment instead of fully replace any performance of surviving and also improving the potential of motor neuron functions. This rehabilitation of motor neurons allows patients a therapeutic approach to recovery opposed to physical structural reconstruction. It is applied in a wide range of disorders of the nervous system, including upper motor neuron dysfunctions like spinal cord injury, cerebral palsy, multiple sclerosis and acquired brain injury including stroke, and neuromuscular diseases as well as for control of pain and spasticity. Instead of applying a reconstructive neurobiological approach, i.e. structural modifications, restorative neurology relies on improving residual function. While subspecialties like neurosurgery and pharmacology exist and are useful in diagnosing and treating conditions of the nervous system, restorative neurology takes a pathophysiological approach. Instead of heavily relying on neurochemistry or perhaps an anatomical discipline, restorative neurology encompasses many fields and blends them together.
Neuromodulation is "the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body". It is carried out to normalize – or modulate – nervous tissue function. Neuromodulation is an evolving therapy that can involve a range of electromagnetic stimuli such as a magnetic field (rTMS), an electric current, or a drug instilled directly in the subdural space. Emerging applications involve targeted introduction of genes or gene regulators and light (optogenetics), and by 2014, these had been at minimum demonstrated in mammalian models, or first-in-human data had been acquired. The most clinical experience has been with electrical stimulation.
Transcranial random noise stimulation (tRNS) is a non-invasive brain stimulation technique and a form of transcranial electrical stimulation (tES). Terney et al from Göttingen University was the first group to apply tRNS in humans in 2008. They showed that by using an alternate current along with random amplitude and frequency in healthy subjects, the motor cortex excitability increased for up to 60 minutes after 10 minutes of stimulation. The study included all the frequencies up to half of the sampling rate i.e. 640 Hz, however the positive effect was limited only to higher frequencies. Although tRNS has shown positive effects in various studies the optimal parameters, as well as the potential clinical effects of this technique, remain unclear.
Gait variability seen in Parkinson's Disorders arise due to cortical changes induced by pathophysiology of the disease process. Gait rehabilitation is focused to harness the adapted connections involved actively to control these variations during the disease progression. Gait variabilities seen are attributed to the defective inputs from the Basal Ganglia. However, there is altered activation of other cortical areas that support the deficient control to bring about a movement and maintain some functional mobility.
Non-invasive cerebellar stimulation is the application of non-invasive neurostimulation techniques on the cerebellum to modify its electrical activity. Techniques such as transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS) can be used. The cerebellum is a high potential target for neuromodulation of neurological and psychiatric disorders due to the high density of neurons in its superficial layer, its electrical properties, and its participation in numerous closed-loop circuits involved in motor, cognitive, and emotional functions.
Alberto Priori is an Italian neurologist, academic, and author. He is a Professor of Neurology at the University of Milan, Director of Neurology 1 Unit at San Paolo Hospital, and the Founder and Coordinator of Aldo Ravelli Center of the University of Milan. He also serves as President of the Neurophysiopatology Techniques Course, and Professor of Postgraduate Schools - Medicine, Healthcare, Dental Medicine at the same University.
Interventional Psychiatry is a subspecialty within the field of psychiatry, focusing on the use of procedural and device-based treatments to manage mental health disorders, particularly those resistant to conventional therapies such as pharmacotherapy and psychotherapy. This field integrates neuromodulation methods with targeted pharmacological interventions, providing options for patients who have not responded to traditional treatments.
Our findings indicates two potential applications for tDCS in the therapeutic arsenal for depression: in primary care settings and as a non-pharmacological, neuromodulatory therapy for depression.
we found tDCS to be efficacious across outcomes in both pairwise and network meta-analyses.